Carna Biosciences, Inc.
FY2026 Q3 Financial Presentation Materials
The company operates two business lines: Drug Discovery and Drug Discovery Support. For the nine months ended Q3, revenue from Drug Discovery Support grew 37.8% year-over-year, while the Drug Discovery segment saw an expanded operating loss due to increased clinical development expenses. Clinical development costs for in-house pipelines (docirbrutinib/sofnobrutinib/monzosertib) rose. Upcoming data presentations at ASH2026 and progress such as ODD designations are notable. Financially, cash increased but liabilities rose, resulting in negative net assets.
Key Figures
- Drug Discovery Support Revenue: 573 million yen (Year-over-Year +178 / +45.1%)
- Drug Discovery Support Operating Loss: -82 million yen
- Drug Discovery Operating Loss: -1,488 million yen
- Research and Development Expenses: 1,461 million yen (Year-over-Year +112)
- Cash and Deposits: 1,241 million yen (vs. prior +65)
AI要約
Business Portfolio and Performance Trends
Carna Biosciences, Inc. operates two segments: Drug Discovery and Drug Discovery Support. For the cumulative Q3 of FY2026, Drug Discovery Support expanded significantly, with revenue of 573 million yen, an increase of 178 million yen and +45.1% year-over-year. Conversely, the Drug Discovery segment was burdened by increased clinical development costs, widening the operating loss. Overall operating loss amounted to 1,532 million yen (Q3 actuals), reflecting delays and increased expenses versus the full-year plan. The company is advancing clinical trials for its in-house pipeline—docirbrutinib, sofnobrutinib, and monzosertib. Data presentations at ASH2026 are planned, and regulatory progress such as ODD designation could act as a tailwind.
Outlook and Impact for Investors
Based on the cumulative Q3 results, Drug Discovery Support is expected to continue growing, while Drug Discovery will require continued investment in clinical development. In 2026, accelerating pipeline clinical development and securing external partnerships will be important. Data disclosures at ASH2026 and progress on ODD designations may expand opportunities for future milestone revenues and licensing-out. On funding, the company has executed financing such as issuance of bonds with warrants to secure a buffer for working capital and R&D expenses.
Drug Discovery Support Revenue Trend
Operating Loss Trend
Regional Revenue Composition (Drug Discovery Support)
R&D Expense Ratio
Carna Biosciences, Inc.
Company overview · Stock price · Financial data · All IR
